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Abstract 
Aims 
Older people increasingly constitute a large proportion of the acute coronary syndrome 
(ACS) population. We examined the relationship of age with receipt of more intensive 
management and secondary prevention medicine. Then, the comparative association of 
intensive management (reperfusion/angiography) over a conservative strategy on time to 
death was investigated by age. 
Methods and Results 
Using data from 155,818 patients in the national registry for ACS in England and Wales (the 
Myocardial Ischaemia National Audit Project (MINAP)), we found that older patients were 
incrementally less likely to receive secondary prevention medicines and intensive 
management for both ST-elevation myocardial infarction (STEMI) and non-ST elevation 
myocardial infarction (NSTEMI). In STEMI patients ≥85 years, 55% received reperfusion 
compared to 84% in those aged 18-<65 (odds ratio 0.22 (95% CI 0.21, 0.24)). Not receiving 
intensive management was associated with worse survival (mean follow-up 2.29 years (SD 
1.42)) in all age groups (adjusted for sex, cardiovascular risk factors, co-morbidities, 
healthcare factors and case severity) but there was an incremental reduction in survival 
benefit from intensive management with increasing age. In STEMI patients aged 18-64, 65-
74, 75-84 and ≥85, adjusted hazard ratios (HRs) for all-cause mortality comparing 
conservative treatment to intensive management were 1.98 (1.78,2.19), 1.65 (1.51,1.80), 1.62 
(1.52,1.72) and 1.36 (1.27,1.47), respectively. In NSTEMI patients, the respective HRs were 
4.37 (4.00, 4.78), 3.76 (3.54, 3.99), 2.79 (2.67, 2.91) and 1.90 (1.77, 2.04).   
Conclusion 
We found an incremental reduction in the use of evidence-based therapies with increasing 
age using a national ACS registry cohort. Whilst survival benefit from more intensive 
management reduced with older age, better survival was associated with intensive 
management at all ages highlighting the requirement to improve standard of care in older 
patients with ACS. 
Keywords: 
Acute Coronary Syndrome; Age; Elderly; Prognosis 
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Introduction 
 Clinical trials of therapies for acute coronary syndrome (ACS) such as coronary 
reperfusion and secondary prevention medicines such as statins have demonstrated 
effectiveness even in the oldest patients (1-2) - however this age group are less likely to 
receive both.(3-5) Such older patients may have increased co-morbidity (6) and higher risk of 
complications from more intensive management (7) and thus this under-treatment relative to 
younger patients may be appropriate. As the population ages and the older age group 
becomes an increasingly larger proportion of the population, it is important to understand 
what effect intensive management is having on outcomes in these older patients, and what 
other additional factors impact on outcomes. 
 Trial evidence on best practice in the older patient with ACS may not represent the 
real-world older ACS patient with multiple co-morbidities. The proportional representation in 
clinical trial populations of older patients is much lower (around 9%) than the real-world 
picture of the acute medical take,(8) where 35% patients are aged 75 or over.(9) There is a 
need for evidence from real-world data that more accurately depicts both receipt of treatment 
and outcomes in the older patient with ACS. Large clinical registries offer representative 
study populations with high generalisability, and importantly the statistical power to answer 
such questions. 
 Using the Myocardial Ischaemia National Audit Project (MINAP), a national registry 
which contains data from patients with an acute coronary syndrome admitted to all 230 
National Health Service (NHS) hospital trusts in England and Wales,(10) we aimed to 
explore the relationship of age group with receipt of more intensive management and 
secondary prevention medicine. Then we aimed to compare the association of intensive 
management on time to death over a conservative strategy by age group, seeking to account 
for any differences in survival through adjustment for co-morbidities, standards of care and 
disease severity, and the interaction of age group with management strategy.  
Methods 
Study design 
 This was a cohort study of patients admitted to hospital with acute coronary syndrome 
and followed up for all-cause mortality. MINAP was set up in 1999 to examine the quality of 
management of acute myocardial infarction in England and Wales and to meet the audit 
requirements of the National Service Framework for Coronary Heart Disease.(11-12) By 
2003, all 230 NHS hospital trusts in England and Wales were contributing data to MINAP. 
Each month, MINAP accrues over 7000 acute coronary syndrome events and records 113 
data fields covering clinical and healthcare-related measures. (10)  Data are collected by 
nurses and clinical audit staff and entered in a dedicated data application (either on-line or 
web based: http://web.nicor.org.uk) developed by the Central Cardiac Audit Database group 
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(13) which is part of the NHS Information Centre for Health and Social Care. MINAP is 
overseen by a multi-professional steering group representing the stakeholders and is based at 
the National Institute for Cardiovascular Outcomes Research (NICOR) at University College 
London. MINAP monitors the completeness of 20 key fields for patients with an admission 
diagnosis of a definite myocardial infarction and the data application contains data validation 
processes including range and consistency checks and also mechanisms to identify and 
remove duplicate records. The patients in MINAP are followed up for their date of all-cause 
death through linkage to the National Health Service Central Registry using a unique number. 
Data entry is subject to routine on-line error checking. MINAP has National Patient 
Information Advisory Group and Central Office for Research Ethics Committees approval for 
individual patient anonymous linkage for mortality. The current study obtained the ethical 
approval from the Faculty of Medicine & Health Sciences Research Ethics Committee, 
University of East Anglia. 
Cohort profile 
 In this paper we used data pertaining to all patients from 2006 to 2010 (the most 
recent download of data with at least one-year follow-up for all-cause mortality). We 
analysed records of admissions between 1st January 2006 and 31st December 2010 for 
patients having a final diagnosis of ST-segment elevation myocardial infarction (STEMI) or 
of non-ST-segment elevation myocardial infarction (NSTEMI). The final diagnosis was 
formed from the history, clinical examination and results of in-patient investigations and was 
made by a senior member of the medical staff. Data were further extensively cleaned by us 
using a priori definitions and a data usage manual written. We further validated variables 
using cross-checks with other data fields – for instance, final diagnosis correlated well with 
elevated markers for STEMI and NSTEMI categories. The original dataset consisted of 
363,098 participants with a final diagnosis of STEMI or NSTEMI (ACS with a positive 
troponin blood test). Of these, 11222 were dropped as one-year follow-up status was 
unknown as were 431 aged under 18 with missing or impossibly high values (>111) for age. 
A further 3729 exclusions included those for whom the census date (at which patients' one-
year follow-up survival status was recorded) preceded the date of hospital admission and 
those in whom survival status was recorded before an entire year had passed since admission. 
Following these exclusions there remained 347,716 observations in the dataset, that is 96% of 
the original dataset. The dataset on which the analyses in this paper are based consists of 
155,818 subjects on whom a complete set of explanatory variables was available. Previous 
published imputation analyses on the MINAP dataset by the lead author(14) have not 
significantly altered effect sizes and imply that missingness in MINAP is at random whilst 
work by others has also shown that the level of missingness of data in MINAP does not alter 
regional standardised mortality ratios.(15) 
Study variables 
 We measured secondary prevention medicine therapy usage by examining receipt of 
aspirin, ACE inhibitor or statin on discharge. With regards to more intensive management, in 
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patients with STEMI this referred to receipt of reperfusion available locally at time of 
presentation (i.e., receipt of thrombolysis or primary percutaneous coronary intervention 
(PPCI)) - centres increasingly shifted to PPCI over the course of the cohort and thus the 
strongest determinant of receipt of either of these treatments was local availability not age). 
In patients with NSTEMI, we regarded more intensive management as receipt of angiography 
in hospital, as previous work in MINAP has shown that any disparity in revascularisation is 
driven primarily by less frequent referral for diagnostic angiogram.(16) The conservative 
group was defined as those who did not receive reperfusion in STEMI patients and those who 
did not receive angiography in NSTEMI patients. These group assignments of intensive 
management and conservative management were defined from the clinical management data 
as recorded by the MINAP clinical audit staff which outlined which treatment modalities 
each patient had undergone in hospital. 
 For survival Cox regression analyses, the outcome was all-cause death. Markers of 
disease severity were collected as in-hospital clinical events of re-infarction, significant 
bleeding (any bleed as recorded by the clinician as well as retroperitoneal and intracranial 
haemorrhage), cardiac arrest and abnormal ECG (e.g. ST or T wave changes or left bundle 
branch block). Co-morbid conditions were chronic renal failure, cerebrovascular disease, 
peripheral vascular disease, chronic obstructive pulmonary disease and congestive cardiac 
failure whilst cardiovascular risk factors were smoking (ex or current), known diabetes 
mellitus and known hypertension (definitions for variables are pre-defined by MINAP and 
given in appendix 1). To account for potential regional differences in care, we used MINAP 
data on the patient's Strategic Health Authority, the regional body that oversees the provision 
of healthcare across a given region within the National Health Service of England and Wales.  
Statistical analysis 
 We examined patient characteristics for the whole ACS cohort by age group (years) at 
presentation categorised as younger (18-<65), young–old (65-<75), old-old (75-< 85) and 
oldest old (≥85) in line with previous work.(17) We applied logistic regression analyses 
separately for STEMI and NSTEMI patients to compare the odds of receipt of treatments for 
ACS against not receiving them - in turn for intensive management, aspirin, ACE inhibitor or 
statin, and by age group using the youngest age group as the reference group on plots. We 
used the chi squared test to assess for trends by age. 
 To investigate whether the association of intensive management on time to death 
within a year of admission compared to the conservative group differed by age group, we 
constructed Cox proportional hazards regression models stratified by age group for STEMI 
and then NSTEMI, using intensive management as the reference group. Logistic regression of 
the whole cohort identified variables that independently contributed to mortality in order to 
build the Cox models. After crude estimates, we in turn adjusted for cardiovascular risk 
factors, co-morbidities, healthcare factors (receipt of secondary prevention and if under the 
care of a cardiologist rather than a generalist) and case severity variables (re-infarction, 
bleeding, cardiac arrest and abnormal ECG) including sex in all these models before building 
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a fully-adjusted combined model. Regression models included Hubert-White robust 
adjustment for intra-cluster correlation of outcomes within Strategic Health Authorities.  
The interactions between the age and management strategy on time to death were evaluated 
separately for both STEMI and NSTEMI using a fully-adjusted model with an interaction 
terms between age group and management strategy. We also examined age-treatment 
interactions within the full model with age modelled as a continuous instead of an ordered 
categorical variable. Wald tests were used to test the significance of age-treatment 
interaction.  
Analyses were performed using Stata SE, version 11 (Stata, College Station, Texas). 
Results 
 The records of 155,818 patients with complete data were examined. Of these, 103,540 
(66.5%) were men. The mean age of the cohort was 69 (SD 14). The mean follow-up was 
2.29 years (SD 1.42). Our final dataset consisted of 68,025 STEMI and 87,793 NSTEMI 
patients. Patients’ baseline characteristics by age group are shown in Table 1 for the whole 
ACS cohort. Younger patients were more likely to be men and smokers than older patients. 
Prevalence of hypertension rose with age though dyslipidaemia fell. Past history of coronary 
disease and co-morbidities rose with age, whilst receipt of previous coronary 
revascularisation decreased with older age and patients who were older were less likely to 
have been cared for by a cardiologist during their admission with an ACS. 
Receipt of management in hospital 
 With older age, patients were less likely to receive secondary prevention medicines 
and intensive management for both STEMI (figure 1) and NSTEMI (figure 2). For STEMI, 
55% of patients aged 85 or over received reperfusion compared to 84% of those patients aged 
18-<65 (odds ratio (OR) 0.22 (95% CI 0.21,0.24). For NSTEMI, the odds of receiving 
coronary angiography were extremely low (OR 0.03 (0.03,0.04)) in the oldest old, with only 
14% of those aged 85 or over undergoing angiography compared to 83% of those patients 
aged 18-<65. Regarding receipt of a statin, STEMI patients aged 85 or over were less likely 
to receive this at discharge compared to patients in the youngest age group (OR 0.31 
(0.29,0.33)). There was an incremental reduction of receipt of treatment with older age for all 
these evidence-based treatments, for both STEMI and NSTEMI. 
Association of older age on adjusted time to death by receipt of intensive management 
 The association of intensive management on time to death over conservative 
management was examined by age strata. In all age groups of patients with STEMI, not 
receiving reperfusion was associated with worse unadjusted survival (table 2). The benefit of 
this intensive management strategy was attenuated in older patients as the hazard ratios 
decrementally approached the reference category with older age groups. After adjusting for 
sex, further adjusting the hazard ratios in separate models (supplementary table 1) for 
cardiovascular risk factors and then for co-morbidities did not alter these results, though 
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when adjusting for healthcare factors (receipt of secondary prevention and care by a 
cardiologist), the adverse prognosis associated with not receiving reperfusion was attenuated 
markedly in the oldest age group (hazard ratio (HR) 1.34 (1.24, 1.44)). Adjusting for factors 
contributing to worse case severity (in-hospital cardiac arrest, in-hospital, re-infarction, 
abnormal ECG, in-hospital bleeding) did not alter these results in any age group. A fully-
adjusted model (table 2) attenuated the worse prognosis in those who did not undergo 
reperfusion in all age groups, in particular for the oldest age group with the effect size 
changing from 1.64 to 1.36, though this is likely to be driven mostly by adjustment for 
healthcare factors. Further accounting for clustering by Strategic Health Authority within the 
fully-adjusted model did not change the point estimates (supplementary table 1).  
 In patients with NSTEMI, conservative management was associated with worse 
unadjusted survival (table 3) in all age groups, but again the benefit of an intensive 
management strategy was attenuated in older patients as the hazard ratios decrementally 
approached the reference category with older age groups. Adjustment for co-morbidities, 
healthcare factors and worse case severity (supplementary table 2) did not significantly alter 
the results for any age group, nor did accounting for clustering by Strategic Health Authority 
within the fully-adjusted model.  
The interaction of age and receipt of intensive investigation 
 For both STEMI and NSTEMI, the fully-adjusted Cox model showed an interaction 
between age group and receipt of intensive investigation (P<0.001 for both). In NSTEMI,  
there was a reduced benefit from receiving intensive management with older age groups 
(final column of table 3), with those undergoing a conservative management strategy aged 85 
or over having a HR of 1.90 (1.77, 2.04) when compared to those undergoing intensive 
management, with the comparable risk of death from a conservative approach being much 
higher (HR 4.37 (4.00, 4.78) in those aged 18-<65. This pattern replicated with STEMI to a 
lesser extent (final column of table 2).  
 Modelling age as a continuous variable, the adjusted hazards ratios for age-treatment 
interaction were 0.989 (0.985-0.992, P<0.001) for STEMI and 0.969 (0.967-0.972, P<0.001) 
for NSTEMI for each extra year of age – thus the increased hazard ratios associated with 
conservative management were reduced by 0.989 and 0.969 respectively for STEMI and 
NSTEMI for each extra year of age. 
Discussion 
 We found an incremental reduction in the use of evidence-based therapies - both 
medicine-based and intensive - with increasing age using a national ACS registry cohort that 
reflects real-world clinical practice in England and Wales and that enabled categorisation of 
ACS patients into STEMI and NSTEMI. We also found that improved survival was 
associated with intensive management at all ages though the difference in survival benefit 
between it and a conservative strategy reduced incrementally with older age. Furthermore, we 
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show that receipt of secondary prevention and care by a cardiologist might be of significant 
benefit in older patients with STEMI in reducing death within one year. 
 Our work correlates with the 2009 UK Department of Health commissioned report 
carried out by the Centre for Policy on Ageing which revealed clear and widespread evidence 
of age discrimination in hospital-based acute investigation and treatment of heart disease and 
in the subsequent instigation of secondary prevention regimes to be carried forward to the 
community following discharge.(18) Despite international guidelines(19) reminding 
clinicians that intensive management in the older patients with ACS is as effective as in their 
younger counterparts, we in line with other studies(17, 20) show that older patients are less 
likely to receive them. We add to this literature by using outcomes out to one year and thus 
presenting a population in which the sickest (who often die in hospital) are less influential in 
the data and which allows clinicians more scope to influence prognosis. We also distinguish 
between the two very different phenotypes that are STEMI and NSTEMI, undertake full 
adjustment for a wide range of prognostic factors within clinically relevant models and use a 
large nationwide registry cohort study highly representative of the real-world ACS 
population. Then importantly, we sought to demonstrate which factors might influence 
longer-term mortality in different age groups in order to facilitate clinical decision-making in 
management. We suggest that an increasing usage of secondary prevention medicine therapy 
and specialist cardiologist input could account for the better outcomes increasingly seen in 
older patients with ACS - previous work in MINAP has revealed incremental reductions in 
short-term (in-hospital) mortality from 2003 to 2010 across all age groups including the 
oldest old. (17) Our work here also confirms ideas from others that improvements in hospital 
care for older patients would reduce mortality rates and that this might be achieved through 
the application of evidence-based ACS therapies to patients regardless of age.(21-22) 
The relative under-treatment of older patients with ACS may be down to a perception on the 
part of the clinician of a higher risk in older patients from intensive management, previous 
analyses in a subset of MINAP (using only those hospitals with interventional facilities) have 
shown that although co-morbidities are associated with higher mortality, the presence of co-
morbidities do not significantly diminish the impact of intensive management on long-term 
mortality.(16) Though bleeding was more common with older age, the prevalence of such 
side effects in our work was low even in those aged 85 and over (2.9% had a significant in-
hospital bleed and in those undergoing reperfusion only 0.84% of this oldest age group had 
an intracranial bleed compared to 0.2% of those aged 18-64 (data not shown)). A single-
centre study from a hospital with interventional facilities also suggested that the lesser 
treatment in older patients cannot be explained by the nature of the healthcare facility they 
are admitted to.(23) On reviewing the literature on clinical trials of an intensive strategy in 
the older patient, these trial patients remain highly selected(24) and there remains a general 
dearth of clinical trial data in older patients.(25) 
 The reduced benefits with older age of intensive management may be due to the 
higher risk of dying from ACS afforded by older age alone (as observed by around a half of 
patients aged 85 years and over in the conservative groups dying within a year),(26) whilst 
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those youngest patients who do not undergo intensive management must have good reason 
not to - such as life-threatening clinical presentations or serious co-morbidity - thus widening 
the relative benefit between intervening intensively or not. Our separate models adjusting for 
potential confounding factors attempted to control for this but were unable to fully explain 
the survival differences between conservative and intensive management strategies. We 
included patients who died in hospital for these analyses to render this paper applicable to 
clinicians who have to make management decisions at the front door. Analysing only those 
that survived to discharge attenuated point estimates (e.g. 2.04 to 1.74 for the fully-adjusted 
model in those NSTEMI patients aged 85 and above, data not shown) but not the overall 
patterns of the results. We found that in the oldest STEMI patients who did not undergo 
reperfusion that receipt of secondary prevention medication and being under the care of a 
cardiologist reduced the relative risk of dying compared to those who did undergo 
reperfusion, suggesting a role for optimised and carefully supervised specialist medicine 
therapy even in those aged 85 and above.  
 What we cannot conclude from this paper is the appropriateness for intensive 
management in the older patient with ACS. It is likely that clinicians are already applying 
clinical judgement in selecting patients for an intensive management strategy, and 
appropriately not intensively managing those patients that are frail, or have extensive co-
morbidity. To a degree thus, the under-management we see in the older age groups here may 
be entirely reasonable but without a randomised controlled clinical trial design in all-comer 
older patients with ACS, criteria for selection for an intensive management strategy will 
remain unclear. Certainly data from other registries suggests that older patients potentially 
stand to gain the most from an intensive management strategy due to their overall highest 
risk, consistent with the substantial impact of age on risk in scores such as the GRACE 
score.(20) However, selection of older patients for an intensive management strategy in the 
real world remains highly variable and they tend to be sicker and have more co-morbidities 
than those recruited in a trial.(27) Even if a trial were planned, it would be unethical to 
randomise all older patients to either strategy as - from clinical trial evidence on highly-
selected older patients - we know that an intensive strategy does work in those selected 
groups, and thus no such trial exists to this day. Any trial in this area would hence need to 
recruit and randomise those older patients in whom there was reasonable doubt as to the 
benefit of an intensive strategy in light of possible harm from such a strategy. What 
constitutes 'reasonable doubt' is however itself far from clear. Teasing out biological age from 
chronological age is perhaps key to this through the judicious use of a wider range of 
prognostic measures to guide the clinician as to the appropriateness of intensive management 
following presentation with ACS. Frailty is estimated to be present in more than 25% in those 
aged 85 and older(28) and some single-item measures (e.g. gait speed measured as 15-foot 
walk time with usual assistive device during the walk) are independently associated with 
mortality risk over follow-up as short as six months in an older population with coronary 
disease(29)  - such measures are feasible in older patients in a clinical trial context(30) and 
may provide supplemental and useful information for clinical discussions about treatment 
risks and benefits. 
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Strengths and Limitations 
 The strength of MINAP is its large size, representativeness and that it contains 
extensive data on clinical management and characterisation. MINAP importantly allowed us 
to take into account the heterogeneity of ACS, as considerable differences exist in the 
pathology and subsequent management of a STEMI compared to a NSTEMI. Though it 
collects data from all 230 hospitals in England and Wales, MINAP cannot collect data on 
every patient with an ACS and it is possible that patients entered into the MINAP database 
differ from those not recorded, and that there may be differences in missingness by age. 
However, older and frailer patients with non-specific symptoms may be less likely to be 
included in registry data and therefore the magnitude of the relationships we observed may 
represent an underestimation. Regarding missing data, some fields were more problematic in 
this regards -  in particular clopidrogrel usage was missing in around half of patients and thus 
could not be used- and which reflects the fact that MINAP is an on-going audit-driven dataset 
that describes evolving healthcare. As iterated above in this paper, missingness is not thought 
to be a major concern in the validity of analyses within MINAP. Future work using MINAP 
in England may be strengthened through the linkage of electronic health records available in 
the Clinical Practice Research Datalink (www.cprd.com) and data on hospital admissions 
from Hospital Episode Statistics.(31) MINAP also lacks data on more detailed clinical 
measures (e.g. acute angiographic findings, presence of acute heart failure (thus not allowing 
us a calculation of a GRACE score(32)), echocardiographic or angiographic measurement of 
ventricular function etc.), the actual time of the angiogram and cause of death. It also did not 
have data on cognition, extreme frailty nor patient choice and its co-morbidity data were 
limited (e.g. no data on cancer) - thus we were unable to explore in greater detail reasons 
underlying the differences in receipt of care by age group, and on survival.  
We also were unable to assess accurately the impact of older age on time from onset of 
symptoms to arrival within MINAP, and the relationship between in-hospital death and 
receipt of either management strategy - however, less than 5% of patients with ACS were 
considered to have had a delay in getting to hospital and of these less than 1% were delays 
associated with transfer, and less than 3% of patients (and less than 5% of patients aged 75-
84) died in hospital. Finally, as an ongoing audit-driven dataset, MINAP spans evolving 
healthcare trends and our data covered the period in which reperfusion was moving from 
thrombolysis to PPCI. We combined these fields as if we were to exclude patients that had 
fibrinolysis, this exclusion would have been driven not by their appropriateness for 
fibrinolysis over PPCI but simply because at the time of their admission, their hospital could 
not offer PPCI. Equally, splitting the STEMI group into fibrinolysis and PPCI would not 
provide a meaningful analysis as the selection would simply be driven by the institution at 
which they were admitted to rather than being a clinically meaningful grouping. That 
fibrinolysis and PPCI are different treatments is less important when compared to the fact that 
they are both tools for reperfusion. By clearly splitting all the cohort analyses into STEMI (in 
whom the decision to reperfuse is made immediately) and NSTEMI (in whom patients are 
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considered for an intensive strategy sometime later in the hospital), we have kept these two 
different ACS phenotypes and their specific management pathways separate. 
Conclusions 
 We found an incremental reduction in the use of evidence-based therapies for ACS 
with older age in the national registry cohort for England and Wales and that better survival 
was associated with intensive management at all ages, though this benefit was attenuated the 
older the patient. Whether the optimal benefit could be achievable by a multidisciplinary care 
model with active involvement of cardiologists in the oldest old requires further evaluation in 
a clinical trial setting. 
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Table 1 Baseline characteristics of whole MINAP cohort 
 <65 65-74 75-84 >85 p-trend 
N  59,994 37,014 38,637 20,173  
SOCIODEMOGRAPHICS      
Age, yrs (mean, SD) 54.4 (7.6) 70.0(2.9) 79.8(2.9) 88.9(3.3) - 
Men (%) 47,713(79.5) 25,102(67.8) 21,853(56.6) 8,872 (44.0) p<0.001 
Current smoker (%) 30,784(51.3) 9,175(24.8) 4,778(12.4) 1,033(5.1) p<0.001 
      
PAST MEDICAL HISTORY      
Diabetic (%) 8,587(14.3) 8,397(22.7) 9,070(23.5) 3,527(17.5) p<0.001 
Hypertensive(%) 22,643(37.7) 19.506(52.7) 22,760(58.9) 11,435(56.7) p<0.001 
Dyslipidaemia (%) 20,144(33.6) 14,282(38.6) 13,283(34.4) 4,975(24.7) p<0.001 
Ischaemic heart disease (%) 9,513 (15.9) 9,340(25.2) 12,368(32.0) 6,941(34.4) p<0.001 
Heart failure(%) 817 (1.4) 1,594(4.3) 3,173(8.21) 2,485(12.3) p<0.001 
Chronic renal failure  (%) 1,057(1.8) 1,613(4.4) 3,103(8.0) 2,020(10.0) p<0.001 
Cerebrovascular disease (%) 1,884(3.1) 3,064(8.3) 4,724(12.2) 2,906(14.4) p<0.001 
Peripheral vascular disease 1,556(2.6) 2,031(5.5) 2,457(6.4) 964(4.8) p<0.001 
Chronic obstructive 6,164(10.3) 6,326(17.1) 7,094(18.4) 2,929(14.5) p<0.001 
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pulmonary disease (%) 
      
PREVIOUS 
REVASCULARISARION 
7,001(11.7) 6,156(16.6) 5,724(14.8) 1,287(6.4) p<0.001 
   Percutaneous Coronary 
Intervention 
5,683(9.5) 4,070(11.0) 3,368(8.7) 779(3.9) p<0.001 
   Coronary bypass surgery 2,010(3.4) 3,035(8.2) 3,168(8.2) 652(3.2) p<0.001 
      
Under Cardiologist care 35,440(59.1) 19,406(52.4) 16,863(43.6) 6,648(33.0) p<0.001 
      
DISCHARGE 
MEDICATIONS 
     
Aspirin 52,054(86.8) 30,738(83.0) 30,309(78.5) 15,192(75.3) p<0.001 
Statin 52,155(86.9) 31,323(84.6) 31,196(80.7) 14,603(72.4) p<0.001 
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B-blocker 47,054(78.4) 26,087(70.5) 24,920(64.5) 11,774(58.4) p<0.001 
ACE inhibitor  48,232(80.4) 28,338(76.6) 27,001(69.9) 11,879(58.9) p<0.001 
      
MARKERS OF DISEASE 
SEVERITY 
     
Abnormal ECG 53,920(89.9) 33,826(91.4) 35,695(92.4) 18,757(92.9) p<0.001 
In-patient re-infarction 1,111(1.9) 740(2.0) 799(2.1) 426(2.1) p=0.005 
In-patient cardiac arrest 2,764(4.6) 1,680(4.5) 1,604(4.2) 717(3.6) p<0.001 
In-patient bleeding 778(1.3) 789(2.1) 1,087(2.8) 580(2.9) p<0.001 
      
DISCHARGE DIAGNOSIS      
   STEMI 33,603(56.0) 16,283(44.0) 12,914(33.4) 5,225(25.9) p<0.001 
   NSTEMI 26,391(44.0) 20,731(56.0) 25,723(66.6) 14,948 (74.1) p<0.001 
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Table 2 Effect of a conservative management strategy compared to receipt of reperfusion on risk of all-cause death by age group for STEMI patients 
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Age 
 
Cases, n  Deaths, n (%) HR (95%CI)
1
 
 
p HR (95%CI)
2 
p HR (95%CI)
3
 p 
18-<65         
Conservative 5234 494 (9.4) 2.22 (2.00,2.46) <0.001 1.96 (1.76,2.18) <0.001 1.98 (1.78,2.19) <0.001 
Reperfusion 28369 1374 (4.8) 1.00 1.00 1.00 
         
65 to 74         
Conservative 3307 737 (22.2) 1.96 (1.80,2.14) <0.001 1.62 (1.48,1.78) <0.001 1.65 (1.51,1.80) <0.001 
Reperfusion 12976 1766 (13.6) 1.00 1.00 1.00 
         
75 to 84         
Conservative 3816 1618 (42.4) 1.91 (1.79,2.03) <0.001 1.63 (1.53,1.74) <0.001 1.62 (1.52,1.72) <0.001 
Reperfusion 9098 2577 (28.3) 1.00 1.00 1.00 
         
≥85 years         
Conservative 2367 1530 (64.6) 1.64(1.53,1.77) <0.001 1.35 (1.25,1.46) <0.001 1.36 (1.27,1.47) <0.001 
Reperfusion 2858 1466 (51.3) 1.00 1.00 1.00 
1 Crude 
17 
 
2 Full model - Adjusted HR for age, sex, diabetes, hypertension and smoking, previous chronic renal failure, cerebrovascular disease, peripheral vascular disease, chronic 
obstructive pulmonary disease and congestive cardiac failure, receipt of ACE inhibitor, statin, aspirin, b-blocker and care by a cardiologist, in-hospital cardiac arrest, in-
hospital re-infarction, abnormal ECG and in-hospital bleeding. Each age stratum had a separate model. 
3 Full model with all patients and interaction term between age and management strategy 
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Table 3 Effect of a conservative management strategy compared to receipt of angiography on risk of all-cause death by age group for NSTEMI patients 
 
 
Age 
 
Cases, n  Deaths, n (%)  HR (95%CI)
1
 
 
p HR (95%CI)
2 
p HR (95%CI)
3
 p 
18-<65         
Conservative 4473 909 (20.3) 4.38 (4.00,4.78) <0.001 3.38 (3.07,3.71) <0.001 4.37 (4.00,4.78) <0.001 
Angiography 21918 1032 (4.7) 1.00 1.00 1.00 
         
65 to 74         
Conservative 6364 2739 (43.0) 3.98 (3.75,4.23) <0.001 3.43 (3.22,3.65) <0.001 3.76 (3.54,3.99) <0.001 
Angiography 14367 1797 (12.5) 1.00 1.00 1.00 
         
75 to 84         
Conservative 14381 7994 (55.6) 2.75 (2.64,2.87) <0.001 2.82 (2.69,2.95) <0.001 2.79 (2.67,2.91) <0.001 
Angiography 11342 2724 (24.0) 1.00 1.00 1.00 
         
≥85 years         
Conservative 12816 8486 (66.2) 1.92 (1.79,2.06) <0.001 2.04 (1.90,2.19) <0.001 1.90 (1.77,2.04) <0.001 
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Angiography 2132 869 (40.8) 1.00 1.00 1.00 
1 Crude 
2 Full model - Adjusted HR for age, sex, diabetes, hypertension and smoking, previous chronic renal failure, cerebrovascular disease, peripheral vascular disease, chronic 
obstructive pulmonary disease and congestive cardiac failure, receipt of ACE inhibitor, statin, aspirin, b-blocker and care by a cardiologist, in-hospital cardiac arrest, in-
hospital re-infarction, abnormal ECG and in-hospital bleeding. Each age stratum had a separate model. 
3 Full model with all patients and interaction term between age and management strategy 
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Figure legends 
Figure 1 Receipt of treatment by age group in patients with STEMI 
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Figure 2 Receipt of treatment by age group in patients with NSTEMI 
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Supplementary tables 
 
Table S1 Effect of a conservative management strategy compared to receipt of reperfusion on risk of all-cause death by age group for STEMI patients 
 
Age 
 
Cases, n  Deaths, n (%)  HR (95%CI)
1
 HR (95%CI)
2 
HR (95%CI)
3
 HR (95%CI)
4
 HR (95%CI)
5
 
18-<65        
Conservative 5234 494 (9.4) 2.14 (1.93,2.38) 2.11 (1.90,2.34) 1.96 (1.76,2.18) 2.37 (2.13,2.63) 1.96 (1.68,2.29) 
Reperfusion 28369 1374 (4.8) 1.00 1.00 1.00 1.00 1.00 
        
65 to 74        
Conservative 3307 737 (22.2) 1.88 (1.73,2.06) 1.78 (1.63,1.95) 1.70 (1.56,1.86) 2.05 (1.88,2.24) 1.62 (1.47,1.80) 
Reperfusion 12976 1766 (13.6) 1.00 1.00 1.00 1.00 1.00 
        
75 to 84        
Conservative 3816 1618 (42.4) 1.88 (1.76,2.00) 1.76 (1.66,1.88) 1.67 (1.57,1.78) 2.04 (1.91,2.17) 1.63 (1.48,1.80) 
Reperfusion 9098 2577 (28.3) 1.00 1.00 1.00 1.00 1.00 
        
≥85 years        
Conservative 2367 1530 (64.6) 1.64 (1.52,1.76) 1.58 (1.47,1.70) 1.34 (1.24,1.44) 1.76 (1.63,1.89) 1.35 (1.20,1.51) 
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Reperfusion 2858 1466 (51.3) 1.00 1.00 1.00 1.00 1.00 
HR for all-cause death  
1 Adjusted HR for sex, diabetes, hypertension and smoking 
2 Adjusted HR for sex, previous chronic renal failure, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease and congestive cardiac 
failure  
3 Adjusted HR for sex, receipt of ACE inhibitor, statin, aspirin, b-blocker and care by a cardiologist 
4 Adjusted HR for sex, in-hospital cardiac arrest, in-hospital re-infarction, abnormal ECG and in-hospital bleeding 
5 Fully adjusted model accounted for clustering by Strategic Health Authority (adjusted HR for sex, diabetes, hypertension and smoking, previous chronic renal failure, 
cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease and congestive cardiac failure, receipt of ACE inhibitor, statin, aspirin, b-blocker 
and care by a cardiologist, in-hospital cardiac arrest, in-hospital re-infarction, abnormal ECG and in-hospital bleeding) 
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Table S2 Effect of a conservative management strategy compared to receipt of angiography on risk of all-cause death by age group for NSTEMI patients 
 
Age 
 
Cases, n  Deaths, n (%)  HR (95%CI)
1
 HR (95%CI)
2 
HR (95%CI)
3
 HR (95%CI)
4
 HR (95%CI)
5
 
<65        
Conservative 5234 909 (20.3) 3.92 (3.58,4.29) 3.34 (3.04,3.66) 4.63 (4.22,5.07) 4.42 (4.04,4.83) 3.38 (2.88,3.95) 
Angiography 28369 1032 (4.7) 1.00 1.00 1.00 1.00 1.00 
        
65 to 74        
Conservative 3307 2739 (43.0) 3.71 (3.50,3.94) 3.38 (3.18,3.59) 4.18 (3.94,4.45) 3.99 (3.76,4.24) 3.43 (3.04,3.87) 
Angiography 12976 1797 (12.5) 1.00 1.00 1.00 1.00 1.00 
        
75 to 84        
Conservative 3816 7994 (55.6) 2.75 (2.63,2.87) 2.57 (2.46,2.69) 3.06 (2.92,3.20) 2.83 (2.71,2.96) 2.82 (2.50,3.17) 
Angiography 9098 2724 (24.0) 1.00 1.00 1.00 1.00 1.00 
        
≥85 years        
Conservative 2367 8486 (66.2) 1.96 (1.83,2.10) 1.92 (1.79,2.06) 2.07 (1.93,2.23) 1.99 (1.85,2.13) 2.04 (1.83,2.28) 
Angiography 2858 869 (40.8) 1.00 1.00 1.00 1.00 1.00 
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HR for all-cause death  
1 Adjusted HR for sex, diabetes, hypertension and smoking 
2 Adjusted HR for sex, previous chronic renal failure, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease and congestive cardiac 
failure  
3 Adjusted HR for sex, receipt of ACE inhibitor, statin, aspirin, b-blocker and care by a cardiologist 
4 Adjusted HR for sex, in-hospital cardiac arrest, in-hospital re-infarction, abnormal ECG and in-hospital bleeding 
5 Fully adjusted model accounted for clustering by Strategic Health Authority (adjusted HR for sex, diabetes, hypertension and smoking, previous chronic renal failure, 
cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease and congestive cardiac failure, receipt of ACE inhibitor, statin, aspirin, b-blocker 
and care by a cardiologist, in-hospital cardiac arrest, in-hospital re-infarction, abnormal ECG and in-hospital bleeding) 
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